Sanofi, created through the acquisition by Sanofi-Synthelabo of Aventis and the subsequent merger into sanofi-aventis in 2004, is one of the leading pharmaceutical companies worldwide and number one in Europe. Headquartered in France, sanofi-aventis operates in 100 countries worldwide with R&D, manufacturing, and commercial business activities. It has almost 100,000 employees.

Sanofi is present in seven major therapeutic fields – Cardiovascular, Thrombosis, Oncology, Internal Nervous System, Diabetes, Internal Medicine, and Vaccines – and it offers a wide range of innovative medicines, mature prescription medicines, Consumer Health Care (CHC), as well as vaccines and aesthetic medicine. After acquisition of Genzyme and Merial in 2011, Sanofi expands its commitment to meeting unfulfilled medical needs in the fields of rare diseases, biosurgery and animal health.

With a global force of research staff working to design new, effective, and well-tolerated medicines and vaccines, sanofi-aventis now has one of the richest and most innovative portfolios of compounds in the whole pharmaceutical industry.

For more information on our company, please visit our website: http://www.sanofi.com (Global website in English) or http://sanofi.com.tw (Taiwan affiliate website in Chinese)